# First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

> **NCT05348889** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chimagen Biosciences, Ltd** · enrollment: 7 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma (disorder)
- Acute Lymphoid Leukemia, Disease (disorder)

## Interventions

- **DRUG:** 1A46 Injection

## Key facts

- **NCT ID:** NCT05348889
- **Lead sponsor:** Chimagen Biosciences, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-30
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sponsor's Research and Development strategy adjustment
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348889, "First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05348889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*